ABK Biomedical Inc.

ABK Biomedical, established in 2012, is dedicated to enhancing treatment options for patients with hypervascular tumors. Their slogan, "Improving treatment options for patients with hypervascular tumors," reflects their mission. The company focuses on research, development, and commercialization of groundbreaking medical device therapies to enhance treatment outcomes for patients with benign and malignant hypervascular tumors. With a multi-disciplinary team experienced in engineering, material science, oncology, medical science, regulatory affairs, finance, business development, sales, marketing, and clinical study coordination, ABK Biomedical has the expertise to advance technology for personalized healthcare in oncology. The company operates in the Biotechnology and Health Care industries, with its headquarters located in Canada. In its most recent funding round, ABK Biomedical secured a $30.00M Series C investment on 06 December 2022 from notable investors including Eight Roads Ventures, F-Prime Capital, and Santé Ventures. ABK Biomedical's innovative approach, specialized team, and recent significant investment position them as a noteworthy player in the medical technology and oncology sectors.